Trials / Conditions / Refractory Primary Mediastinal Large B-Cell Lymphoma

Refractory Primary Mediastinal Large B-Cell Lymphoma

10 registered clinical trials studyying Refractory Primary Mediastinal Large B-Cell Lymphoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell T NCT07365306	City of Hope Medical Center	Phase 2
Recruiting	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lym NCT07098364	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726	University of Washington	Phase 2
Recruiting	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373	Mayo Clinic	Phase 2
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse NCT06271057	The Lymphoma Academic Research Organisation	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Active Not Recruiting	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymph NCT05359211	Fred Hutchinson Cancer Center	Phase 1
Completed	Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell NCT03484819	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2